Denali Says Hunter Syndrome Candidate Lowers Disease-Associated Biomarker

Denali Therapeutics Inc DNLI announced new interim results from the ongoing open-label, single-arm Phase 1/2 study of DNL310 IDS in children with MPS II (Hunter syndrome).

Among the 13 participants who reached two years of treatment at the time of the interim analysis, a mean reduction of 64% (p<0.001) from baseline in serum neurofilament light (NfL) was observed. 

NfL is a key biomarker of neurodegeneration.

Also Read: Also Read: Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure.

The FDA recently recommended to Denali the assessment of NfL as an exploratory endpoint to assess its potential as a possible biomarker to assess diagnostic, prognostic, or therapeutic response in subjects with aneuronopathic MPS II. 

DNL310 is an investigational brain-penetrant enzyme replacement therapy designed to address the behavioral, cognitive, and physical manifestations of MPS II. The global Phase 2/3 COMPASS study is ongoing. 

Additional interim data from the Phase 1/2 study of DNL310 will be highlighted in an oral presentation at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023 in Jerusalem, Israel, August 29 – September 1, 2023.

Price Action: DNLI shares are up 2.74% at $31.89 on the last check Tuesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!